Mycophenolate (CellCept) During Pregnancy: Why It's Avoided

What does the evidence say about mycophenolate during pregnancy?

1. MotherToBaby describes mycophenolate as CellCept and related products, summarizes reported miscarriage and birth-defect concerns, and advises contacting healthcare providers after exposure. 1
2. A teratogenicity review describes first-trimester pregnancy loss and clustered findings including microtia, cleft lip or palate, limb, diaphragmatic, and cardiac anomalies, while emphasizing limited absolute-risk data. 2
3. A separate review describes mycophenolate embryopathy and notes that the FDA REMS includes birth-control counseling counseling and a registry for exposures during pregnancy or within six weeks after stopping. 3
4. A kidney-transplant review states that mycophenolate products are associated with miscarriage and structural defects and are generally stopped at least six weeks before planned conception when feasible. 4
5. MotherToBaby describes required pregnancy testing before mycophenolate and again eight to ten days after starting. Effective contraception continues during use and for six weeks afterward, and mycophenolate can reduce the effectiveness of birth-control pills. 1

Is mycophenolate safe in each trimester?

• First trimester. First-trimester mycophenolate exposure is the period most associated with reported pregnancy loss and structural defects. Contact the prescriber promptly for an individualized switch or monitoring plan rather than stopping suddenly.
• Second trimester. A pregnancy discovered after early exposure still warrants prompt transplant or specialist review. Imaging and maternal disease control may be discussed, but a past exposure does not predict an individual outcome.
• Third trimester. Tell the delivery and newborn teams about current or recent mycophenolate exposure and the underlying transplant or autoimmune condition. The medication plan should remain coordinated through specialists.